Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RNTX
REIN THERAPEUTICS INC.
NASDAQ
$0.76
▼ DOWN 2.64% (-0.02)

KEY STATISTICS

Market Cap$21.31 M
52w High$2.18
52w Low$0.69
Dividend Yield—
Frequency—
P/E-0.48
Volume258.03K
Shares Out.27.96M

COMPANY

LEADERSHIP

James Brian Windsor
CHIEF EXECUTIVE
James Brian Windsor

COMPENSATION 2026

Salary$575,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$20,195
Total$882,695

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 29, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
10

PRICE TARGET

Target High$6.00
Target Low$6.00
Target Median$6.00
Target Consensus$6.00

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.—
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2022-11-11Reverse1:20

PRICE

$0.76 ▼ DOWN 2.64% (−$0.02)
OVERLAYS
$0.77$0.77$0.78$0.799:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM0.76

About Rein Therapeutics Inc.

http://www.reintx.com ↗

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel cancer therapeutics, including ALRN-6924, a peptide that reactivates p53 tumor suppression in wild-type p53 cancers.

INDUSTRY

Biotechnology

A PRODUCT REIN THERAPEUTICS INC. IS KNOWN FOR

LTI-03
LTI-03

LTI-03, Rein Therapeutics' lead Phase 2 drug for IPF, is a synthetic peptide targeting alveolar cell survival and profibrotic signaling, with Orphan Drug status, focusing on rare pulmonary and fibrotic diseases.

COMPETITORS

COMPETITOR
BMY COMPARE
INSM COMPARE
LQDA COMPARE
PLRX COMPARE
UTHR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
1
RANKED BY POSITION SIZE
VTS.AX
0.00% · 2.5M

INSTITUTIONAL OWNERSHIP

SHARES OWNED
38.12%
HOLDERS
60
TOP 12 OF 60 · RANKED BY POSITION SIZE
Voss Capital, LLC
4.4M sh · $5.7M
Bios Capital Management, LP
2.0M sh · $2.58M
Vanguard Group Inc
1.2M sh · $1.34M
Prosight Management, LP
567.9K sh · $650.24K
University Of Texas/Texas Am Investment Managment Co
511.6K sh · $665.09K
Cable Car Capital LLC
420.0K sh · $546K
Sigma Planning Corp
348.7K sh · $453.28K
Geode Capital Management, LLC
344.7K sh · $448.19K
Texas Capital Bank Wealth Management Services Inc
273.6K sh · $355.71K
Gagnon Securities LLC
240.2K sh · $278.65K
Senvest Management, LLC
230.9K sh · $267.84K
Palogic Value Management, L.P.
180.0K sh · $234K

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
DIRECTOR
VON RICKENBACH JOSEF H
Purchase · 4.5K shares
2026-05-27
★
DIRECTOR
VON RICKENBACH JOSEF H
Purchase · 23.2K shares
2026-05-26
★
DIRECTOR
VON RICKENBACH JOSEF H
Purchase · 15.9K shares
2026-05-22
★
DIRECTOR
VON RICKENBACH JOSEF H
Purchase · 3.4K shares
2026-05-21

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
HOLD 1
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Brookline Capital HOLD

SECTORS PEERS

PEERPRICE
CELU$1.58COMPARE
YI$3.55COMPARE
BEAT$0.47COMPARE
QNTM$3.08COMPARE
TPST$1.06COMPARE
BCAB$1.74COMPARE